Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | ADCs for the treatment of myeloma

Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, gives an overview of the mechanism of action of anti-BCMA antibody-drug conjugates (ADCs) which are used in the treatment of multiple myeloma. ADCs have been shown to work by mediating apoptosis and phagocytosis as well as immunogenic cell death of the myeloma cells via immuno-independent and immuno-dependent means, respectively. Immunogenic cell death mediated by such agents has offered an explanation for how patients who have demonstrated discontinued treatment may still demonstrate a maintained response. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.